Latest news with #Salipro
Korea Herald
2 days ago
- Business
- Korea Herald
Daewoong partners with Sweden's Salipro to boost drug discovery
Daewoong Pharmaceutical on Wednesday announced a strategic research partnership with Swedish biotech company Salipro Biotech to jointly develop next-generation therapeutics targeting membrane proteins. Under the agreement, Salipro will provide Daewoong access to its proprietary Salipro Platform, a technology that stabilizes membrane proteins in a near-native environment, making them more accessible for drug discovery. Membrane proteins are involved in essential cellular functions and account for over 60 percent of known drug targets, yet their structural instability in lab conditions has long been a barrier to research. The partnership is Salipro's first with a Korean company and follows previous collaborations with major pharmaceutical firms including Boehringer Ingelheim, Sanofi and Sumitomo. Daewoong views the alliance as a key step in its open innovation strategy, aiming to bolster its global competitiveness and lay the groundwork for potential overseas licensing deals. 'Our partnership with Daewoong marks Salipro's first collaboration with a Korean company, making it especially meaningful,' Jens Frauenfeld, CEO of Salipro Biotech, stated. 'The Salipro platform enables research on previously inaccessible target proteins and is expected to unlock new possibilities in global innovative drug development.' Park Seong-soo, CEO of Daewoong Pharmaceutical, added, 'We expect that the Salipro platform will enhance our access to challenging membrane protein targets and accelerate our drug discovery efforts. Through an open collaboration strategy, we will continue to develop globally competitive new drugs.'
Yahoo
14-03-2025
- Business
- Yahoo
Boehringer Ingelheim and Salipro enter drug discovery partnership
Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a research and licence agreement to expedite the development of several drug targets. The partnership is set to progress the discovery and development of new therapeutic solutions that target G protein-coupled receptors (GPCRs), transporters and ion channels, which are crucial in cardio-renal-metabolic and mental health diseases. Salipro platform technology will be leveraged in the partnership. This platform stabilises membrane proteins in their native states, facilitating their usage in drug discovery programmes. It brings together Salipro Biotech's expertise and its platform technology for stabilising targets from the drug discovery programmes of Boehringer, enabling and expediting the development of new therapeutics. Boehringer plans to carry out structural and biophysical studies which include cryo-electron microscopy on its pipeline targets to detect potential candidates. Boehringer will provide Salipro with research and option payments. Salipro is qualified for success-based milestone payments contingent on the developmental outcomes produced by Boehringer under this partnership. Salipro Biotech CEO Jens Frauenfeld stated: 'We are excited to collaborate with the innovative teams at Boehringer Ingelheim. 'By combining our Salipro platform technology with Boehringer Ingelheim's expertise in biophysical and structural studies, we enable new possibilities in drug discovery and development.' The Swedish company has established several research partnerships with pharmaceutical and biotech entities. It aims to expedite drug discovery via in-house and collaborated pipelines. In December 2024, the company announced the receipt of patents granted for its Salipro platform technology in both Australia and Singapore. It also facilitates drug discovery programmes, which include screening small molecule drugs, structure-based drug design and antibody discovery. In October 2023, Salipro Biotech entered a multi-target antibody research agreement with Icosagen, a biotech company. "Boehringer Ingelheim and Salipro enter drug discovery partnership" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
